Sector
PharmaceuticalsOpen
₹1,585.8Prev. Close
₹1,585.8Turnover(Lac.)
₹6,484.82Day's High
₹1,625.05Day's Low
₹1,570.152 Week's High
₹1,708.6552 Week's Low
₹1,052Book Value
₹267.91Face Value
₹1Mkt Cap (₹ Cr.)
40,128.4P/E
57.54EPS
27.5Divi. Yield
0.25This consolidation aims to streamline all of Ipca Group's US generics formulations under a single entity, enhancing operational efficiency.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 25.37 | 25.37 | 25.37 | 25.37 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 6,323.34 | 5,851.93 | 5,450.39 | 4,727.35 |
Net Worth | 6,348.71 | 5,877.3 | 5,475.76 | 4,752.72 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 5,399.36 | 5,139.16 | 4,337.82 | 3,193.4 |
yoy growth (%) | 5.06 | 18.47 | 35.83 | 2.93 |
Raw materials | -1,763.12 | -1,582.48 | -1,480.7 | -1,112.48 |
As % of sales | 32.65 | 30.79 | 34.13 | 34.83 |
Employee costs | -1,089.63 | -948.84 | -870.79 | -712.78 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 1,088.36 | 1,379.96 | 784.97 | 282.8 |
Depreciation | -204.1 | -187.72 | -178.69 | -174.36 |
Tax paid | -217.42 | -239.19 | -132.51 | -49.69 |
Working capital | 484.48 | 421.93 | 376.59 | 222.97 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 5.06 | 18.47 | 35.83 | 2.93 |
Op profit growth | -17.84 | 65.46 | 107.12 | 2.25 |
EBIT growth | -21.07 | 73.34 | 160.98 | 8.97 |
Net profit growth | -23.65 | 74.84 | 179.89 | 23.8 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 7,705.04 | 6,244.32 | 5,829.79 | 5,419.99 | 4,648.71 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 7,705.04 | 6,244.32 | 5,829.79 | 5,419.99 | 4,648.71 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 124.77 | 125.62 | 66.57 | 62.84 | 67 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,819 | 158.19 | 4,36,103.12 | 863.29 | 0.74 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,782.35 | 83.58 | 1,53,540.39 | 518 | 0.52 | 2,302 | 513.62 |
Mankind Pharma Ltd MANKIND | 2,910.6 | 59.91 | 1,20,073.47 | 634.43 | 0 | 2,529.74 | 334.18 |
Cipla Ltd CIPLA | 1,475.75 | 28.16 | 1,19,195.76 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,399.45 | 70.36 | 1,15,106.89 | 460 | 0.82 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Premchand Godha
Managing Director & CFO
A K Jain
Managing Director & CEO
Pranay Godha
Executive Director
Prashant Godha
Independent Non Exe. Director
Kamal Kishore Seth
Independent Non Exe. Director
Narendra Mairpady
Company Sec. & Compli. Officer
Harish P Kamath
Independent Director
Swati Patankar
Independent Director
Vivek Shiralkar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ipca Laboratories Ltd
Summary
Ipca Laboratories Limited (IPCA) was incorporated on 19th October, 1949 under the name of The Indian Pharmaceutical Combine Association Limited. Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 APIs covering various therapeutic segments. The products of the Company are now sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations for the world market.Ipcas APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries. Ipca is one of the biggest manufacturers in the world of APIs Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over. The name of the company was changed to Ipca Laboratories Limited in 6th August of the year 1964 and again name was changed to Ipca Laboratories Private Limited in 13th January of the year 1966. Ipca had commissioned one of the first modern Pharma factory of yesteryears
Read More
The Ipca Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1581.7 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ipca Laboratories Ltd is ₹40128.40 Cr. as of 24 Dec ‘24
The PE and PB ratios of Ipca Laboratories Ltd is 57.54 and 5.96 as of 24 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Ipca Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ipca Laboratories Ltd is ₹1052 and ₹1708.65 as of 24 Dec ‘24
Ipca Laboratories Ltd's CAGR for 5 Years at 22.39%, 3 Years at 16.07%, 1 Year at 49.41%, 6 Month at 40.55%, 3 Month at 6.87% and 1 Month at -1.58%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice